Biosimilars – Forecast – Endocrinology
In 2023, sales of insulins at the ex-manufacturer price level exceeded $19 billion in the major pharmaceutical markets under study (United States, EU5, and Japan); G7 sales for Prolia exceeded $3 billion. Throughout our 2023-2033 forecast period, the originator insulins manufactured by Eli Lilly, Novo Nordisk, and Sanofi as well as Amgen / Daiichi Sankyo’s Prolia / Pralia will face increasing competition from biosimilars / follow-on insulins, eroding both patient share and drug prices. We present our forecast for key reference brand insulins and antiresorptive analogues and their biosimilars / follow-on insulins by therapeutic area, molecule, and country / region.
Table of contents
- Biosimilars - Forecast - Endocrinology
Related Market Assessment Reports
Report
Diabetic Macular Edema / Diabetic Retinopathy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Diabetic macular edema (DME), a complication of diabetic retinopathy (DR), develops as a result of persistently elevated blood sugar levels and can lead to vision loss or blindness if left…
Report
Opioid-Induced Constipation – Current Treatment – Treatment Algorithms: Claims Data Analysis – Opioid-Induced Constipation (US)
Opioid-induced constipation (OIC) is a condition in which bowel movements are infrequent or incomplete as a result of opioid medications. The treatment of OIC relies on various prescription…
